scholarly journals Acanthamoeba polyphaga

2020 ◽  
Author(s):  
Keyword(s):  
Acanthamoeba Polyphaga

Characterization of an aminotransferase from Acanthamoeba polyphaga Mimivirus

2021 ◽  
Author(s):  
Chase A. Seltzner ◽  
Justin D. Ferek ◽  
James B. Thoden ◽  
Hazel M. Holden
Keyword(s):  
Acanthamoeba Polyphaga ◽  
Acanthamoeba Polyphaga Mimivirus

Amebicidal activity of the essential oils of Lippia spp. (Verbenaceae) against Acanthamoeba polyphaga trophozoites

2015 ◽  
Vol 115 (2) ◽  
pp. 535-540 ◽  
Author(s):  
Israel Gomes de Amorim Santos ◽  
Ricardo Scher ◽  
Marilise Brittes Rott ◽  
Leociley Rocha Menezes ◽  
Emmanoel Vilaça Costa ◽  
...  
Keyword(s):  
Essential Oils ◽  
Acanthamoeba Polyphaga ◽  
Amebicidal Activity

scholarly journals Acanthamoeba polyphaga-Enhanced Growth of Mycobacterium smegmatis

PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e29833 ◽  
Author(s):  
Otmane Lamrabet ◽  
Felix Mba Medie ◽  
Michel Drancourt
Keyword(s):  
Mycobacterium Smegmatis ◽  
Acanthamoeba Polyphaga

Defined Minimal Growth Medium for Acanthamoeba polyphaga

1983 ◽  
Vol 30 (3) ◽  
pp. 606-608
Author(s):  
CONNIE S. INGALLS ◽  
MORGAN M. BRENT
Keyword(s):  
Growth Medium ◽  
Acanthamoeba Polyphaga ◽  
Minimal Growth

scholarly journals Azole Antifungal Agents To Treat the Human Pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through Inhibition of Sterol 14α-Demethylase (CYP51)

2015 ◽  
Vol 59 (8) ◽  
pp. 4707-4713 ◽  
Author(s):  
David C. Lamb ◽  
Andrew G. S. Warrilow ◽  
Nicola J. Rolley ◽  
Josie E. Parker ◽  
W. David Nes ◽  
...  
Keyword(s):  
Antifungal Agents ◽  
Acanthamoeba Castellanii ◽  
Therapeutic Agents ◽  
Effective Inhibitor ◽  
Human Pathogens ◽  
Acanthamoeba Polyphaga ◽  
Binding Studies ◽  
Content Type ◽  
Inhibition Concentration

ABSTRACTIn this study, we investigate the amebicidal activities of the pharmaceutical triazole CYP51 inhibitors fluconazole, itraconazole, and voriconazole againstAcanthamoeba castellaniiandAcanthamoeba polyphagaand assess their potential as therapeutic agents againstAcanthamoebainfections in humans. Amebicidal activities of the triazoles were assessed byin vitrominimum inhibition concentration (MIC) determinations using trophozoites ofA. castellaniiandA. polyphaga. In addition, triazole effectiveness was assessed by ligand binding studies and inhibition of CYP51 activity of purifiedA. castellaniiCYP51 (AcCYP51) that was heterologously expressed inEscherichia coli. Itraconazole and voriconazole bound tightly to AcCYP51 (dissociation constant [Kd] of 10 and 13 nM), whereas fluconazole bound weakly (Kdof 2,137 nM). Both itraconazole and voriconazole were confirmed to be strong inhibitors of AcCYP51 activity (50% inhibitory concentrations [IC50] of 0.23 and 0.39 μM), whereas inhibition by fluconazole was weak (IC50, 30 μM). However, itraconazole was 8- to 16-fold less effective (MIC, 16 mg/liter) at inhibitingA. polyphagaandA. castellaniicell proliferation than voriconazole (MIC, 1 to 2 mg/liter), while fluconazole did not inhibitAcanthamoebacell division (MIC, >64 mg/liter)in vitro. Voriconazole was an effective inhibitor of trophozoite proliferation forA. castellaniiandA. polyphaga; therefore, it should be evaluated in trials versus itraconazole for controllingAcanthamoebainfections.

Sign in / Sign up

Export Citation Format

Share Document